Product: Occludin Antibody
Catalog: DF7504
Description: Rabbit polyclonal antibody to Occludin
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat, Pig
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 23~30kD, 52~65kD; 59kD(Calculated).
Uniprot: Q16625
RRID: AB_2841004

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:1000-3000, IHC 1:50-1:200, IF/ICC 1:200
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(80%)
Occludin Antibody detects endogenous levels of total Occludin.
Cite Format: Affinity Biosciences Cat# DF7504, RRID:AB_2841004.
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


BLCPMG; FLJ08163; FLJ18079; FLJ77961; FLJ94056; MGC34277; Occludin; Ocln; OCLN_HUMAN; Tight junction protein occludin;



Localized at tight junctions of both epithelial and endothelial cells. Highly expressed in kidney. Not detected in testis.




Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q16625 As Substrate

Site PTM Type Enzyme
S8 Phosphorylation
K18 Ubiquitination
S40 Phosphorylation
Y44 Phosphorylation
S45 Phosphorylation
K276 Ubiquitination
S277 Phosphorylation
K283 Ubiquitination
Y287 Phosphorylation
K299 Ubiquitination
S302 Phosphorylation
T305 Phosphorylation
S310 Phosphorylation
S313 Phosphorylation
Y315 Phosphorylation
S321 Phosphorylation
Y325 Phosphorylation
S326 Phosphorylation
S327 Phosphorylation
K330 Ubiquitination
Y337 Phosphorylation
S340 Phosphorylation
S341 Phosphorylation
Y342 Phosphorylation
K343 Ubiquitination
S344 Phosphorylation
T345 Phosphorylation
S358 Phosphorylation
Y368 Phosphorylation
S369 Phosphorylation
S370 Phosphorylation
T376 Phosphorylation
S378 Phosphorylation
K379 Ubiquitination
T393 Phosphorylation
Y398 Phosphorylation P12931 (SRC)
T400 Phosphorylation P68400 (CSNK2A1)
Y402 Phosphorylation P12931 (SRC)
T403 Phosphorylation Q02156 (PRKCE) , P24723 (PRKCH) , Q05513 (PRKCZ)
T404 Phosphorylation Q02156 (PRKCE) , Q05513 (PRKCZ) , P24723 (PRKCH) , P68400 (CSNK2A1) , P67870 (CSNK2B)
S408 Phosphorylation P67870 (CSNK2B) , P68400 (CSNK2A1)
T424 Phosphorylation Q02156 (PRKCE) , Q05513 (PRKCZ)
T438 Phosphorylation Q02156 (PRKCE) , Q05513 (PRKCZ)
Y443 Phosphorylation
S445 Phosphorylation
S448 Phosphorylation
S458 Phosphorylation
Y467 Phosphorylation
S471 Phosphorylation
Y474 Phosphorylation
Y481 Phosphorylation
K488 Ubiquitination
S490 Phosphorylation P05771 (PRKCB)

Research Backgrounds


May play a role in the formation and regulation of the tight junction (TJ) paracellular permeability barrier. It is able to induce adhesion when expressed in cells lacking tight junctions.


Dephosphorylated by PTPRJ. The tyrosine phosphorylation on Tyr-398 and Tyr-402 reduces its ability to interact with TJP1. Phosphorylation at Ser-490 also attenuates the interaction with TJP1.

Subcellular Location:

Cell membrane>Multi-pass membrane protein. Cell junction>Tight junction.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Localized at tight junctions of both epithelial and endothelial cells. Highly expressed in kidney. Not detected in testis.

Subunit Structure:

Interacts with TJP1/ZO1. Interacts with VAPA. Interacts with CLDN1, CLDN6, CLDN9, CLDN11, CLDN12 and CLDN17.


The C-terminal is cytoplasmic and is important for interaction with ZO-1. Sufficient for the tight junction localization. Involved in the regulation of the permeability barrier function of the tight junction (By similarity). The first extracellular loop participates in an adhesive interaction.

Belongs to the ELL/occludin family.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cell adhesion molecules (CAMs).   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Pathogenic Escherichia coli infection.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Organismal Systems > Immune system > Leukocyte transendothelial migration.   (View pathway)


1). Liu L et al. Extracellular vesicles of Fusobacterium nucleatum compromise intestinal barrier through targeting RIPK1-mediated cell death pathway. Gut Microbes 2021;13(1):1-20. (PubMed: 33769187) [IF=12.2]

Application: IHC    Species: mouse    Sample: colon

Figure 5. |FnEVs increase gut barrier leakage in experimental colitis models. (a) Representative images and ex vivo imaging with the intestine, liver, heart, spleen and kidney of mice. (b) Relative fluorescence intensity of translocated EGFP-labeled E.coli in every tissues. (c) Representative images of immunohistochemical stainings of ZO-1, claudin-1 and occludin in the colon on day 3 after colitis induction. Scale bar = 50 um.

2). Bai X et al. Water-extracted Lonicera japonica polysaccharide attenuates allergic rhinitis by regulating NLRP3-IL-17 signaling axis. Carbohydrate Polymers 2022 Dec 1;297:120053. (PubMed: 36184153) [IF=11.2]

3). Liu S et al. Low dose of arsenic exacerbates toxicity to mice and IPEC-J2 cells exposed with deoxynivalenol: Aryl hydrocarbon receptor and autophagy might be novel therapeutic targets. Science of The Total Environment 2022 Apr 2;155027. (PubMed: 35381244) [IF=9.8]

4). Li X et al. Multistage-Responsive Nanocomplexes Attenuate Ulcerative Colitis by Improving the Accumulation and Distribution of Oral Nucleic Acid Drugs in the Colon. ACS Applied Materials & Interfaces 2022 Jan 12;14(1):2058-2070. (PubMed: 34978415) [IF=9.5]

5). Li C et al. Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-κB pathway. PHARMACOLOGICAL RESEARCH 2019 Dec 18:104603 (PubMed: 31863867) [IF=9.3]

Application: WB    Species: Mice    Sample: colonic tissues

Fig. 4. OBB protected intestinal epithelial barrier by modulating TJs proteins. Effect of OBB on the mRNA levels of mucin-1(A) and mucin-2 (B). (C) Representative Western blotting images of TJs protein, and the relative protein expressions were normalized to β-actin. (D-H) Changes in the relative protein expression levels of ZO-1, ZO-2, occludin, JAM-A, and claudin-1 were measured respectively. Data are shown as mean ± SEM (n = 3). # P < 0.05, ## P < 0.01 vs. Control group, * P < 0.05, ** P < 0.01 vs. DSS group, & P < 0.05, && P < 0.01 vs. BBR group.

6). Wang Y et al. Fourteen composite probiotics alleviate type 2 diabetes through modulating gut microbiota and modifying M1/M2 phenotype macrophage in db/ db mice. PHARMACOLOGICAL RESEARCH 2020 Nov;161:105150. (PubMed: 32818655) [IF=9.3]

Application: IHC    Species: mouse    Sample: colon

Fig. 4.| Effects of the composite probiotics on intestinal barrier function.The protein expression of claudin-1 (G), occludin-1 (H), ZO-1 (I) and mucin-2 (J)determined by immunohistochemistry (original magnification 200×) (n = 4 images/group).

7). Zhao C et al. Gut microbiota-mediated secondary bile acid alleviates Staphylococcus aureus-induced mastitis through the TGR5-cAMP-PKA-NF-κB/NLRP3 pathways in mice. npj Biofilms and Microbiomes 2023 Feb 8;9(1):8. (PubMed: 36755021) [IF=9.2]

8). Liu J et al. Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism. npj Biofilms and Microbiomes 2023 May 31;9(29) (PubMed: 37258543) [IF=9.2]

9). Zhao C et al. Commensal cow Roseburia reduces gut-dysbiosis-induced mastitis through inhibiting bacterial translocation by producing butyrate in mice. Cell Reports 2022 Nov 22;41(8):111681. (PubMed: 36417859) [IF=8.8]

Application: WB    Species: Mouse    Sample:

Figure 2FMT from cows with mastitis to mice induces mastitis and disrupts the blood-milk and gut barrier in mice

10). Xiao H et al. Tremella fuciformis polysaccharides ameliorated ulcerative colitis via inhibiting inflammation and enhancing intestinal epithelial barrier function. International Journal of Biological Macromolecules 2021 Mar 17;180:633-642. (PubMed: 33744251) [IF=8.2]

Application: IF/ICC    Species: mouse    Sample: colon

Fig. 3. |Effect of TFP on intestinal barrier in DSS-induced colitis mice. (A) Representative TEM images in colon tissues (white arrows indicate TJs, black arrows indicate intestinal villi loss).(B) The mRNA level of TJP1 in colon tissues. (C) The mRNA level of OCLN in colon tissues. (D) The fluorescence intensity of ZO-1. (E) The fluorescence intensity of occludin.(F) Representative fluorescent images of ZO-1 and occludin in colon tissues. All data were shown as mean ± SEM. (n = 6 for each group). ⁎P < 0.05. ⁎⁎P < 0.01 compared with control group; #P < 0.05. ##P < 0.01 compared with DSS group.

Load more

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.